We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.00 | 23.00 | 25.00 | 24.00 | 24.00 | 24.00 | 72,159 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -3.42M | -0.0317 | -7.57 | 25.91M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 03/10/2024 20:03 | Oh and remember that the individuals that were VERY focused re the RF debacle and that domino effect across multiple discussion boards/ companies...individu Rf are a shark. Remember Puma and his mate were pushing Prem! Look at that company now Nasty bits of work. | criticalthinker1 | |
| 03/10/2024 18:43 | Henry. Its a shame one has to respond to disrupters with the detail you have given. But well done. Personally I don't suffer fools gladly. Not specifically re your response but I can definitely agree with your response re attaining information from posters. A neighbour of mine who moved away a couple years ago is an individual who is very quiet but VERY clever. He sold his company (albeit employed again to run his ipr) that is being used by the US government to attain information from hard drives that what individuals think is deleted...isn't. I can put him in contact with your own endeavours if he is accepting of the idea. But I might add he is a grey man. Moving on.... Interesting posts re our potential worth. I would like to remind individuals of this re our 1801 being very successful in ARDS re 'covid' albeit being a coronavirus....so remember 1801 went in vivo in 2021!! This is an extract of the RNS. London South East Rainbow Rare Earths discuss progress and continued flowsheet optimisation at Phalaborwa Project. Watch the interview here. Less Ads, More Data, More Tools Register for FREE Share PricesSareum Share PriceSareum Share Regulatory NewsCovid-19 Research Project Results Pin to quick picksSareum Regulatory News (SAR) SAR Share Price SAR Share Price SAR Share News SAR Share News SAR Share Chat SAR Share Chat 46 SAR Share Trades SAR Share Trades 15 SAR Live RNS SAR Live RNS Sponsored Content Sareum Information Buy SAR Shares Buy SAR Shares Add SAR to Watchlist Add SAR to Watchlist Add SAR to Alert Add SAR to Alert SAR Live PriceLast checked at 19:07:41 Share Price Information for Sareum (SAR) London Stock Exchange Share Price is delayed by 15 minutes Get Live Data Share Price: 27.50 Bid: 27.00 Ask: 28.00 Change: 0.50 (1.85%) Spread: 1.00 (3.704%)Open: 27.00High: 27.50Low: 27.00Prev. Close: 27.00 Sponsored Content Covid-19 Research Project Results 1 Jul 2021 07:00 RNS Number : 7338D Sareum Holdings PLC 01 July 2021 Sareum Holdings PLC ("Sareum" or the "Company") Completed Covid-19 Research Project Delivers Encouraging Results Cambridge, UK, 1 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project. The aim of this research project was to investigate the effects of SDC-1801, the Company's proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801. The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor. Subsequent completed in-vivo studies support the initial cellular results and indicate: · Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and that · Viral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model. And then the shenanigans became apparent. I've been a continuous supporter of Sareum and made my points clear about decisions that were not correct..but I firmly feel we have been under attack. I mean a buy is quickly followed by a sell and then relatively noteable buys are imo supported by sells that cover them...as if a company is drip feeding a client.. All best Steadydanny So much more to say but will hold back. | criticalthinker1 | |
| 03/10/2024 18:31 | Henry. Its a shame one has to respond to disrupters with the detail you have given. But well done. Personally I don't suffer fools gladly. Not specifically re your response but I can definitely agree with your response re attaining information from posters. A neighbour of mine who moved away a couple years ago is an individual who is very quiet but VERY clever. He sold his company (albeit employed again to run his ipr) that is being used by the US government to attain information from hard drives that what individuals think is deleted...isn't. I can put him in contact with your own endeavours if he is accepting of the idea. But I might add he is a grey man. Moving on.... Interesting posts re our potential worth. I would like to remind individuals of this re our 1801 being very successful in ARDS re 'covid' albeit being a coronavirus....so remember 1801 went in vivo in 2021!! This is an extract of the RNS. London South East Rainbow Rare Earths discuss progress and continued flowsheet optimisation at Phalaborwa Project. Watch the interview here. Less Ads, More Data, More Tools Register for FREE Share PricesSareum Share PriceSareum Share Regulatory NewsCovid-19 Research Project Results Pin to quick picksSareum Regulatory News (SAR) SAR Share Price SAR Share Price SAR Share News SAR Share News SAR Share Chat SAR Share Chat 46 SAR Share Trades SAR Share Trades 15 SAR Live RNS SAR Live RNS Sponsored Content Sareum Information Buy SAR Shares Buy SAR Shares Add SAR to Watchlist Add SAR to Watchlist Add SAR to Alert Add SAR to Alert SAR Live PriceLast checked at 19:07:41 Share Price Information for Sareum (SAR) London Stock Exchange Share Price is delayed by 15 minutes Get Live Data Share Price: 27.50 Bid: 27.00 Ask: 28.00 Change: 0.50 (1.85%) Spread: 1.00 (3.704%)Open: 27.00High: 27.50Low: 27.00Prev. Close: 27.00 Sponsored Content Covid-19 Research Project Results 1 Jul 2021 07:00 RNS Number : 7338D Sareum Holdings PLC 01 July 2021 Sareum Holdings PLC ("Sareum" or the "Company") Completed Covid-19 Research Project Delivers Encouraging Results Cambridge, UK, 1 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project. The aim of this research project was to investigate the effects of SDC-1801, the Company's proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801. The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor. Subsequent completed in-vivo studies support the initial cellular results and indicate: · Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and that · Viral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model. And then the shenanigans became apparent. I've been a continuous supporter of Sareum and made my points clear about decisions that were not correct..but I firmly feel we have been under attack. I mean a buy is quickly followed by a sell and then relatively noteable buys are imo supported by sells that cover them...as if a company is drip feeding a client.. All best Steadydanny So much more to say but will hold back. | criticalthinker1 | |
| 02/10/2024 21:47 | Again nothing specific...just a response of a derogatory demeanor. 30. | criticalthinker1 | |
| 02/10/2024 21:41 | Just waiting... Another 20 years... Many happy returns... Year of the rerate etc... | wolfofwallstreets | |
| 02/10/2024 20:20 | Wolf you never give a balanced post ....EVER! You attack individuals after their reasoned discussion backed up with valid background information that is pertinent to their point, and creates an interesting discussion. Everyone is on the spectrum, to varying degrees. A majority of the best inventions and observations comes from those who are not just another brick in the wall.Some admit it. Some brush over and get angry because they can't back up their position without any worthwhile clarity. Just droll on wirh this bad and always bad ...it's because they are effectively psychopaths or in this instance paid for disruption. so deep into the spectrum they are in denial. You fit a window of quite worrying traits with your responses. Literally makes one feel they should call the relevant parties to advise you are an issue. | criticalthinker1 | |
| 02/10/2024 10:03 | What a disgusting and lying pig of a person you are | horridhenry | |
| 01/10/2024 14:12 | MongHenry...great to see you posting again.. you have gone quiet since the most recent declines. Still...I'm sure news is just around the corner...it always is... I truly believe a top 10 uni cares about the posts on a BB about an AIM share which is close to collapse. In the real.world...nobody really cares about sareum. Good try tho. Weren't you the one who claimed you were selling screen shots.. but forgot your story and claimed you were giving them to your daughter.. who I'm sure you molested... That I am a laughing stock on lse is ironic given they keep posting the same dreck over and over is certainly ironic...When's that takeover happening?! You must be enjoying your time away to post on here...Hahaha... Great you brought some more... More money to be lost... Nope...still not cubanpete.. I was thoth though... Had to kill off that ID as my claims were just sooooo stupid. Hahaha.. | wolfofwallstreets | |
| 30/9/2024 23:10 | Wolf do you follow opera? Check out Smilyana Zaharieva... Enjoy. | criticalthinker1 | |
| 30/9/2024 18:21 | Just looked and shock horror... Market cap is less than 30 million.. Wasn't this supposed to be worth billions by now... Great to see sadoldtart on lse back to his old trope of war and peace posts .. Even he admitted his posting was pointless... | wolfofwallstreets | |
| 27/9/2024 14:48 | No takeover this week? Hahaha... Must be next week... | wolfofwallstreets | |
| 26/9/2024 17:05 | Lots of sells coming in.. Must "believe in the science"... | wolfofwallstreets | |
| 25/9/2024 21:37 | Great to see lse ramper-in-chief sadoldtart ramping posts again.. He can't help himself... Even after saying his posts were pointless... "Goodbye for a while...maybe a long while.." | wolfofwallstreets | |
| 25/9/2024 20:10 | ? I don't understand yor point.? So the ipr is worth zero in your ipinion? Please explain your reasoning wolf so I can assimilate to your investment knowledge. What else you looking at | criticalthinker1 | |
| 25/9/2024 18:54 | The potential for sareum doesn't existing outside of BBs by deluded rampers.... Look at the share chart... All the way down to 0 No takeover interest even as the market cap fell down to 10 million.... You are delusional... | wolfofwallstreets | |
| 25/9/2024 18:47 | And it's so disinteresting wolf that you continually post negative sentiment. Go figure. Basic question. Do you understand the indications of uracil over tyrosine, previously known as thymine? AGCT. Then work in RNA. URACIL. Which replaces tyrosine albeit it removes the ability of tyrosine to remove cytosine. Which normally tyrosine removes cytosine. Which leads to cytosine which leads to cytokine storms and cytotoxicity! Noticing any indications of an untick in autoimmune concerns? You never talk about its possibilities. The individual I know from ... was aware imo. | criticalthinker1 | |
| 25/9/2024 18:22 | Lol... You've been spewing the same rubbish now for years... Let the bidding begin... Gsk handed back 737... Nobody wants sareums molecules... You talk utter tripe... Even cheerleader ramper sadoldtart has given up... | wolfofwallstreets |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
